509 related articles for article (PubMed ID: 25475459)
1. Comparison of outcomes after cardioversion or atrial fibrillation ablation in patients with differing periprocedural anticoagulation regimens.
Kochhäuser S; Khaykin Y; Beardsall J; Juta R; Hache P; Trought K; Lenton-Brym T; Tsang B; Pantano A; Beardsall M; Wulffhart Z; Verma A
Can J Cardiol; 2014 Dec; 30(12):1541-6. PubMed ID: 25475459
[TBL] [Abstract][Full Text] [Related]
2. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.
Piccini JP; Stevens SR; Lokhnygina Y; Patel MR; Halperin JL; Singer DE; Hankey GJ; Hacke W; Becker RC; Nessel CC; Mahaffey KW; Fox KA; Califf RM; Breithardt G;
J Am Coll Cardiol; 2013 May; 61(19):1998-2006. PubMed ID: 23500298
[TBL] [Abstract][Full Text] [Related]
3. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial.
Di Biase L; Burkhardt JD; Santangeli P; Mohanty P; Sanchez JE; Horton R; Gallinghouse GJ; Themistoclakis S; Rossillo A; Lakkireddy D; Reddy M; Hao S; Hongo R; Beheiry S; Zagrodzky J; Rong B; Mohanty S; Elayi CS; Forleo G; Pelargonio G; Narducci ML; Dello Russo A; Casella M; Fassini G; Tondo C; Schweikert RA; Natale A
Circulation; 2014 Jun; 129(25):2638-44. PubMed ID: 24744272
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
Providência R; Marijon E; Albenque JP; Combes S; Combes N; Jourda F; Hireche H; Morais J; Boveda S
Europace; 2014 Aug; 16(8):1137-44. PubMed ID: 24550347
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation.
Nairooz R; Sardar P; Pino M; Aronow WS; Sewani A; Mukherjee D; Paydak H; Maskoun W
Int J Cardiol; 2015; 187():345-53. PubMed ID: 25839640
[TBL] [Abstract][Full Text] [Related]
6. Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation.
Trujillo TC; Dobesh PP; Crossley GH; Finks SW
Pharmacotherapy; 2019 Jan; 39(1):94-108. PubMed ID: 30548542
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion.
Ezekowitz MD; Cappato R; Klein AL; Camm AJ; Ma CS; Le Heuzey JY; Talajic M; Scanavacca MI; Vardas PE; Kirchhof P; Hohnloser SH; Hemmrich M; Lanius V; Meng IL; Wildgoose P; van Eickels M
Am Heart J; 2014 May; 167(5):646-52. PubMed ID: 24766973
[TBL] [Abstract][Full Text] [Related]
8. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.
Lakkireddy D; Reddy YM; Di Biase L; Vallakati A; Mansour MC; Santangeli P; Gangireddy S; Swarup V; Chalhoub F; Atkins D; Bommana S; Verma A; Sanchez JE; Burkhardt JD; Barrett CD; Baheiry S; Ruskin J; Reddy V; Natale A
J Am Coll Cardiol; 2014 Mar; 63(10):982-8. PubMed ID: 24412445
[TBL] [Abstract][Full Text] [Related]
9. Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation.
Eitel C; Koch J; Sommer P; John S; Kircher S; Bollmann A; Arya A; Piorkowski C; Hindricks G
Europace; 2013 Nov; 15(11):1587-93. PubMed ID: 23703362
[TBL] [Abstract][Full Text] [Related]
10. Novel Oral Anticoagulants in Direct Current Cardioversion for Atrial Fibrillation.
Femia G; Fetahovic T; Shetty P; Lee A
Heart Lung Circ; 2018 Jul; 27(7):798-803. PubMed ID: 28802808
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial.
Chi G; Kerneis M; Kalayci A; Liu Y; Mehran R; Bode C; Halperin JL; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Peterson ED; Fox KAA; Gibson CM
Am Heart J; 2018 Sep; 203():17-24. PubMed ID: 30015064
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).
Flaker G; Lopes RD; Al-Khatib SM; Hermosillo AG; Hohnloser SH; Tinga B; Zhu J; Mohan P; Garcia D; Bartunek J; Vinereanu D; Husted S; Harjola VP; Rosenqvist M; Alexander JH; Granger CB;
J Am Coll Cardiol; 2014 Mar; 63(11):1082-7. PubMed ID: 24211508
[TBL] [Abstract][Full Text] [Related]
13. Low stroke risk after elective cardioversion of atrial fibrillation: an analysis of the Flec-SL trial.
Apostolakis S; Haeusler KG; Oeff M; Treszl A; Andresen D; Borggrefe M; Lip GY; Meinertz T; Parade U; Samol A; Steinbeck G; Wegscheider K; Breithardt G; Kirchhof P
Int J Cardiol; 2013 Oct; 168(4):3977-81. PubMed ID: 23871349
[TBL] [Abstract][Full Text] [Related]
14. Patterns of oral anticoagulation use with cardioversion in clinical practice.
Geurink K; Holmes D; Ezekowitz MD; Pieper K; Fonarow G; Kowey PR; Reiffel JA; Singer DE; Freeman J; Gersh BJ; Mahaffey KW; Hylek EM; Naccarelli G; Piccini JP; Peterson ED; Pokorney SD
Heart; 2021 Apr; 107(8):642-649. PubMed ID: 32591363
[TBL] [Abstract][Full Text] [Related]
15. Risk of stroke after catheter ablation versus cardioversion for atrial fibrillation: A propensity-matched study of 24,244 patients.
Noseworthy PA; Kapa S; Deshmukh AJ; Madhavan M; Van Houten H; Haas LR; Mulpuru SK; McLeod CJ; Asirvatham SJ; Friedman PA; Shah ND; Packer DL
Heart Rhythm; 2015 Jun; 12(6):1154-61. PubMed ID: 25708883
[TBL] [Abstract][Full Text] [Related]
16. Oral anticoagulant therapy for stroke prevention in patients with atrial fibrillation undergoing ablation: results from the First European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA).
Potpara TS; Larsen TB; Deharo JC; Rossvoll O; Dagres N; Todd D; Pison L; Proclemer A; Purefellner H; Blomström-Lundqvist C;
Europace; 2015 Jun; 17(6):986-93. PubMed ID: 26023177
[TBL] [Abstract][Full Text] [Related]
17. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio.
Di Biase L; Burkhardt JD; Mohanty P; Sanchez J; Horton R; Gallinghouse GJ; Lakkireddy D; Verma A; Khaykin Y; Hongo R; Hao S; Beheiry S; Pelargonio G; Dello Russo A; Casella M; Santarelli P; Santangeli P; Wang P; Al-Ahmad A; Patel D; Themistoclakis S; Bonso A; Rossillo A; Corrado A; Raviele A; Cummings JE; Schweikert RA; Lewis WR; Natale A
Circulation; 2010 Jun; 121(23):2550-6. PubMed ID: 20516376
[TBL] [Abstract][Full Text] [Related]
18. Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter.
Yadlapati A; Groh C; Passman R
Am J Cardiol; 2014 Apr; 113(8):1362-3. PubMed ID: 24576547
[TBL] [Abstract][Full Text] [Related]
19. Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants.
Brinkmeier-Theofanopoulou M; Tzamalis P; Wehrkamp-Richter S; Radzewitz A; Merkel M; Schymik G; van Mark G; Bramlage P; Schmitt C; Luik A
BMC Cardiovasc Disord; 2018 Apr; 18(1):71. PubMed ID: 29703158
[TBL] [Abstract][Full Text] [Related]
20. Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry.
Papp J; Zima E; Bover R; Karaliute R; Rossi A; Szymanski C; Troccoli R; Schneider J; Fagerland MW; Camm AJ; Atar D
Eur Heart J Cardiovasc Pharmacother; 2017 Jul; 3(3):147-150. PubMed ID: 28329309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
